Analyzing immune characteristics in neurodegenerative diseases
Immunohistochemical Study of Peripheral Blood Mononuclear Cells in Sporadic Alzheimer's Disease and Dementia With Lewy Body
This study is testing how the immune cells in people with Alzheimer's Disease and Dementia with Lewy Bodies are different to help doctors better understand and diagnose these conditions.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 55 Years to 100 Years |
| Sex | All |
| Sponsor | First Affiliated Hospital of Zhejiang University Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT05518409 on ClinicalTrials.gov |
What this trial studies
This study utilizes cytof technology to analyze peripheral blood mononuclear cells (PBMC) from patients with sporadic Alzheimer's Disease (AD) and Dementia with Lewy Bodies (DLB). The goal is to identify immune differences between these two neurodegenerative diseases at the single-cell level, which will help in building immune models and enhancing the precision of clinical diagnoses. By focusing on molecular immunity, the study aims to provide objective support for differentiating between AD and DLB.
Who should consider this trial
Good fit: Ideal candidates include individuals clinically diagnosed with Alzheimer's Disease or Dementia with Lewy Bodies.
Not a fit: Patients with infectious diseases, autoimmune diseases, or other specified exclusions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic accuracy and tailored treatment strategies for patients with neurodegenerative diseases.
How similar studies have performed: While similar studies have explored immune characteristics in neurodegenerative diseases, this specific approach using cytof technology is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. AD inclusion criteria: a.Clinical diagnosis of Alzheimer's Disease 2. DLB inclusion criteria: 1. Clinical diagnosis of Dementia with Lewy bodies Exclusion Criteria: 1. Infectious diseases 2. autoimmune disease 3. heart failure 4. chronic obstructive pulmonary disease (COPD) 5. cancer 6. renal failure 7. recently major surgery 8. alcohol and / or drug abuse 9. disturbance of consciousness 10. clinical diagnosis of major depression disorder 11. clinical diagnosis of Anxiety disorder
Where this trial is running
Hangzhou, Zhejiang
- Department of Psychiatry, First Affiliated Hospital of Zhejiang University — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Hu ShaoHua
- Email: dorhushaohua@zju.edu.cn
- Phone: 086-13957162903
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.